BaroFold Grants Protein Technology Research License to Pfizer
News Jan 10, 2007
BaroFold, Inc. has announced the granting of a multi-site research license to Pfizer, Inc. for BaroFold's proprietary PreEMT™ high pressure technology for solubilizing, disaggregating and refolding proteins.
Financial terms were not disclosed. Pfizer joins several other biotechnology firms and pharmaceutical corporations who have licensed BaroFold's technology to refold and produce proteins.
"We are pleased to be working with Pfizer, a global leader in discovering and developing breakthrough medicines," said Lyndal Hesterberg, President and CEO of BaroFold Inc.
"The use of the BaroFold technology has broken a log-jam for many companies in target discovery for developing clean three-dimensional protein structures for crystallography and rational drug design. PreEMT technology has been validated by various partners through use in over two hundred proteins. We hope to support future development of important therapeutic programs at Pfizer."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE